IONS - Ionis Pharmaceuticals, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
IPO Date: December 22, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $7.2B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.00 | 2.13%
Avg Daily Range (30 D): $1.53 | 2.98%
Avg Daily Range (90 D): $1.40 | 2.36%
Institutional Daily Volume
Avg Daily Volume: 1.26M
Avg Daily Volume (30 D): 3M
Avg Daily Volume (90 D): 2.64M
Trade Size
Avg Trade Size (Sh.): 80
Avg Trade Size (Sh.) (30 D): 79
Avg Trade Size (Sh.) (90 D): 74
Institutional Trades
Total Institutional Trades: 13,413
Avg Institutional Trade: $3.08M
Avg Institutional Trade (30 D): $4.32M
Avg Institutional Trade (90 D): $4.51M
Avg Institutional Trade Volume: .06M
Avg Institutional Trades (Per Day): 4
Market Closing Trades
Avg Closing Trade: $7.86M
Avg Closing Trade (30 D): $32.39M
Avg Closing Trade (90 D): $29.78M
Avg Closing Volume: 161.54K
 
News
Oct 8, 2026 @ 3:19 PM
NVS Wins FDA Nod for Label Expansion of Immunology...
Source: Na
Oct 5, 2026 @ 3:21 PM
Novartis Strengthens RNA Therapeutics Pipeline Wit...
Source: Na
Oct 1, 2026 @ 4:30 PM
Royalty Pharma Owns a Piece of 16 Blockbuster Drug...
Source: Thomas Niel
Sep 28, 2026 @ 9:23 AM
18 of 21 Analysts Still Think Alnylam Stock Is a B...
Source: Keith Speights
Sep 23, 2026 @ 4:13 PM
Ionis Delivers Positive Late-Stage Results for Two...
Source: Na
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-.47 $-.69 $-.56
Diluted EPS $-.55 $-.69 $-.56
Revenue $874.09M $267.95M $246.09M
Gross Profit $858.07M $265.21M $243.11M
Net Income / Loss $-83.62M $-114.65M $-92.53M
Operating Income / Loss $-594.36M $-102.29M $-117.42M
Cost of Revenue $16.02M $2.74M $2.98M
Net Cash Flow $53.07M $176.73M $-198.74M
PE Ratio